US · Healthcare · Biotechnology
EPS came in at -1.53 against a street estimate of -1.40 — a miss of 9.3%.
Analysts rate Neurogene Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $80.43.
| Fund | Stake |
|---|---|
| Samsara BioCapital, LLC | 8.58% |
| Casdin Capital, LLC | 7.72% |
| Redmile Group, LLC | 7.06% |
| RTW INVESTMENTS, LLC | 6.81% |
| EcoR1 Capital, LLC | 6.35% |
| BlackRock Inc | 5.02% |
| Baker Bros Advisors LP | 4.96% |
| Balyasny Asset Management LLC | 3.59% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 NEUROGENE INC. – Q2 2026 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $112.5 million in cash and cash equivalents, plus $112. | 2026-08-11 |
| Results announced · Q3 2026 NEUROGENE CORPORATION - AUGUST 2026 CORPORATE PRESENTATION SUMMARY HEADLINE NUMBERS • Phase 1/2 Trial (N=10): 100% of participants gained ≥1 develop | 2026-08-11 |
| Material agreement · Q2 2026 NEUROGENE INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed public offering of 3,500,000 shares at $30.00 per share • Additional 666,666 | 2026-07-02 |
| Reg FD disclosure · Q2 2026 NEUROGENE INC. - 8-K FILING SUMMARY Report Date: June 29, 2026 --- HEADLINE NUMBERS • Company: Neurogene Inc. (Nasdaq: NGNE) • Announcement Date: J | 2026-06-29 |
| Reg FD disclosure · Q2 2026 NEUROGENE INC. (NGNE) – FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial figures or numerical results are disclosed in this Form 8-K filing | 2026-06-08 |
| Quarterly report · Q1 2026 NEUROGENE INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments: $243.2 million (cash $124.2M + short-term investments $119.0M) as of Ma | 2026-05-12 |
| Proxy statement · Q2 2026 NEUROGENE INC. PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Rachel McMinn (Executive Chair, Founder and CEO) Total 2025 Compensation: Not separat | 2026-04-16 |
| Annual report FY2025 NEUROGENE INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net Loss (FY 2025): $90.4 million | FY 2024: $75.1 million • Accumulated Defic | 2026-03-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neurogene Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.